A recent study demonstrated the potential of a specific inhibitor of BET proteins (iBET) to inhibit proliferation of myeloproliferative neoplasms driven by constitutively active Janus kinase 2 (JAK2) (64). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.